Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115130) titled 'Genetic Risk of the Retinoic Acid Signaling Pathway in Schizophrenia' on Dec. 23, 2025.
Study Type: Observational study
Study Design:
Case-Control study
Primary Sponsor: Henan Mental Hospital
Condition:
schizophrenia
Intervention:
Schizophrenia group:none
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-01-01
Target Sample Size: Schizophrenia group:500;Healthy control group:500;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=298550
Published by HT Digital Content Services with permission from Health Daily Digest....